Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma,申请号US201214110869-传众专利搜索

Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma

申请公布号：US9302967(B2)

申请号：US201214110869

申请日期：2012.04.11

申请公布日期：2016.04.05

申请人：

Council of Scientific & Industrial Research

发明人：Bandyopadhyay Santu;Ghosh Balaram;Jaisankar Parasuraman;Pal Bikas Chandra;Roy Siddhartha;Paul Bholanath;Ram Arjun;Mabalirajan Ulaganathan;Ali Nahid;Bandopadhyay Arun;Konar Aditya;Chakraborty Jayashree Bagchi;Mukherjee Indrani Choudhury;Chaudhuri Jaydeep;Mahato Sanjit Kumar;Manna Anirban;Sinha Roma;Bhattacharya Pradyot;Vinayagam Jayaraman;Jana Deba Prasad;Chowdhury Sushovan

分类号：A61K31/14;A61K31/05;C07C39/19;A61K31/15;A61K31/215;A61K31/277;A61K31/36;C07C69/017;C07C69/732;C07C251/40;C07C251/66;C07C255/36;C07D317/50

主分类号：A61K31/14

代理机构：

Potter Anderson & Corroon LLP

代理人：Potter Anderson & Corroon LLP

地址：Rafi Marg IN

摘要：The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.

主权项：1. A method for the treatment of a mammal suffering from bronchial asthma consisting essentially of administering to the mammal in need thereof a therapeutically effective amount of: i. one or more compounds general formula 1 having the structure: wherein R1=—H or —COCH3, R2=—H or —COCH3, or wherein R1 and R2 are covalently coupled to —CH2— comprising a five member ring with the structure: wherein R4=—H or —CH2—CH═CH2 or —CH2—CH2—CH3 wherein R5=—H or —CH2—CH═CH2; andwherein R6=—H or —CH2—CH═CH2; ii. one or more compounds with formula I having the structure: wherein R1=—H or —COCH3, R2=—H or —COCH3, or wherein R1 and R2 are covalently coupled to —CH2— comprising a five member ring with the structure: wherein R3=—H;wherein R4=—CH═CH2 or —CH2—CH3 or —CH═NOH or —CN or —CH═NOAc or —CH═CH—COOEt;wherein R5=—H or —CH2—CH═CH2;wherein R6=—H or —CH2—CH═CH2 wherein R=—H or —CH3; andwherein R8=—H or —CH3; iii. one or more compounds with formula II having the structure: wherein R1=—H or —COCH3, R2=—H or —COCH3, or wherein R1 and R2 are covalently coupled to —CH2— comprising a five member ring with the structure: wherein R3=—CH═CH2 wherein R4=—H or —CH2—CH═CH2 or —CH2—CH2—CH3;wherein R5=—H or —CH2—CH═CH2;wherein R6=—H or —CH2—CH═CH2;wherein R7=—H; andwherein R8=—H; andwherein the bronchial asthma is treated by IL-4 or IL-5 pathway inhibition.